{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:59:33Z","timestamp":1790276373021,"version":"4.1.0"},"reference-count":395,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS120926"],"award-info":[{"award-number":["R01NS120926"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS127188"],"award-info":[{"award-number":["R01NS127188"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centers for Disease Control and Prevention\/Agency for Toxic Substances and Disease Registry","award":["R01TS000344"],"award-info":[{"award-number":["R01TS000344"]}]},{"name":"Centers for Disease Control and Prevention\/Agency for Toxic Substances and Disease Registry","award":["R01TS000327"],"award-info":[{"award-number":["R01TS000327"]}]},{"name":"James and Margaret Hiller and Linda and Eric Novak"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40263-025-01217-0","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:06:01Z","timestamp":1756825561000},"page":"949-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations"],"prefix":"10.1007","volume":"39","author":[{"given":"Savannah E.","family":"Quigley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-2298","authenticated-orcid":false,"given":"Kellen H.","family":"Quigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-6637","authenticated-orcid":false,"given":"Stephen A.","family":"Goutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"10360","key":"1217_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363\u201380.","journal-title":"Lancet"},{"key":"1217_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes11010001","author":"F Vignaroli","year":"2023","unstructured":"Vignaroli F, et al. The need for biomarkers in the ALS-FTD spectrum: a clinical point of view on the role of proteomics. Proteomes. 2023. https:\/\/doi.org\/10.3390\/proteomes11010001.","journal-title":"Proteomes"},{"issue":"5","key":"1217_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/acn3.51762","volume":"10","author":"TC Larson","year":"2023","unstructured":"Larson TC, et al. Causes of death among United States decedents with ALS: an eye toward delaying mortality. Ann Clin Transl Neurol. 2023;10(5):757\u201364.","journal-title":"Ann Clin Transl Neurol"},{"key":"1217_CR4","first-page":"1","volume":"2023","author":"P Mehta","year":"2018","unstructured":"Mehta P, et al. Prevalence of amyotrophic lateral sclerosis in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2018;2023:1\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"1217_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1212\/WNL.0000000000200799","volume":"99","author":"H Mitsumoto","year":"2022","unstructured":"Mitsumoto H, Kasarskis EJ, Simmons Z. Hastening the diagnosis of amyotrophic lateral sclerosis. Neurology. 2022;99(2):60\u20138.","journal-title":"Neurology"},{"issue":"11","key":"1217_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jamaneurol.2019.2044","volume":"76","author":"M Ryan","year":"2019","unstructured":"Ryan M, et al. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76(11):1367\u201374.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1217_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","volume":"21","author":"SA Goutman","year":"2022","unstructured":"Goutman SA, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465\u201379.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1217_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22(3):185\u2013212.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1217_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.15252\/emmm.201708202","volume":"10","author":"ME Umoh","year":"2018","unstructured":"Umoh ME, et al. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48\u201362.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(24)00479-4","volume":"24","author":"M Benatar","year":"2025","unstructured":"Benatar M, Robertson J, Andersen PM. Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention. Lancet Neurol. 2025;24(1):77\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1217_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00401-019-01998-x","volume":"138","author":"L Marrone","year":"2019","unstructured":"Marrone L, et al. Fus pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138(1):67\u201384.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1217_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-013-1125-6","volume":"125","author":"AM Blokhuis","year":"2013","unstructured":"Blokhuis AM, et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777\u201394.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1217_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000492946","volume":"18","author":"J Adams","year":"2018","unstructured":"Adams J, Lee M, Peng W. Critical review of complementary and alternative medicine use in amyotrophic lateral sclerosis: prevalence and users\u2019 profile, decision-making, information seeking, and disclosure in the face of a lack of efficacy. Neurodegener Dis. 2018;18(4):225\u201332.","journal-title":"Neurodegener Dis"},{"issue":"8","key":"1217_CR14","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/acn3.52140","volume":"11","author":"SA Goutman","year":"2024","unstructured":"Goutman SA, et al. ALS identified: two-year findings from a sponsored ALS genetic testing program. Ann Clin Transl Neurol. 2024;11(8):2201\u201311.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"1217_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/practneurol-2021-002989","volume":"22","author":"T Dharmadasa","year":"2022","unstructured":"Dharmadasa T, et al. Genetic testing in motor neurone disease. Pract Neurol. 2022;22(2):107\u201316.","journal-title":"Pract Neurol"},{"issue":"11","key":"1217_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/nn.2660","volume":"13","author":"DA Bosco","year":"2010","unstructured":"Bosco DA, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11):1396\u2013403.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1217_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, et al. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1): 267.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1217_CR18","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290\u20136.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"1217_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/17482960903545334","volume":"11","author":"AC Ludolph","year":"2010","unstructured":"Ludolph AC, et al. Guidelines for preclinical animal research in ALS\/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11(1\u20132):38\u201345.","journal-title":"Amyotroph Lateral Scler"},{"key":"1217_CR20","doi-asserted-by":"publisher","first-page":"2909168","DOI":"10.1155\/2019\/2909168","volume":"2019","author":"M Babic Leko","year":"2019","unstructured":"Babic Leko M, et al. Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav Neurol. 2019;2019:2909168.","journal-title":"Behav Neurol"},{"issue":"9","key":"1217_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s12264-020-00567-7","volume":"36","author":"Z Hao","year":"2020","unstructured":"Hao Z, et al. Role of the C9ORF72 gene in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. Neurosci Bull. 2020;36(9):1057\u201370.","journal-title":"Neurosci Bull"},{"issue":"3","key":"1217_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00415-025-12975-8","volume":"272","author":"P Ruffo","year":"2025","unstructured":"Ruffo P, Traynor BJ, Conforti FL. Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects. J Neurol. 2025;272(3):233.","journal-title":"J Neurol"},{"issue":"2","key":"1217_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1474-4422(24)00517-9","volume":"24","author":"TG Moens","year":"2025","unstructured":"Moens TG, et al. Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications. Lancet Neurol. 2025;24(2):166\u201378.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1217_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jnnp-2017-316174","volume":"88","author":"L Pozzi","year":"2017","unstructured":"Pozzi L, et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J Neurol Neurosurg Psychiatry. 2017;88(10):869\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1217_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00415-025-13153-6","volume":"272","author":"V Pensato","year":"2025","unstructured":"Pensato V, et al. Exploring NEK1 genetic variability in Italian amyotrophic lateral sclerosis patients. J Neurol. 2025;272(7):469.","journal-title":"J Neurol"},{"key":"1217_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.833051","volume":"16","author":"N Riva","year":"2022","unstructured":"Riva N, et al. NEK1 variants in a cohort of Italian patients with amyotrophic lateral sclerosis. Front Neurosci. 2022;16: 833051.","journal-title":"Front Neurosci"},{"key":"1217_CR27","unstructured":"Amyotrophic lateral sclerosis: developing drugs for treatment guidance for industry. Food and Drug Administration. 2019."},{"issue":"12","key":"1217_CR28","first-page":"1331","volume":"90","author":"RPA van Eijk","year":"2019","unstructured":"van Eijk RPA, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90(12):1331\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"1217_CR29","first-page":"77","volume":"17","author":"B Marin","year":"2015","unstructured":"Marin B, et al. Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1\u20132):77\u201384.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1\u20132","key":"1217_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1\u20132):13\u201321.","journal-title":"J Neurol Sci"},{"issue":"19","key":"1217_CR31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","volume":"83","author":"N Atassi","year":"2014","unstructured":"Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719\u201325.","journal-title":"Neurology"},{"issue":"6","key":"1217_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/jnnp-2015-310998","volume":"87","author":"J Labra","year":"2016","unstructured":"Labra J, et al. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1217_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265\u20137.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1217_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3109\/17482960903093710","volume":"11","author":"C Castrillo-Viguera","year":"2010","unstructured":"Castrillo-Viguera C, et al. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1\u20132):178\u201380.","journal-title":"Amyotroph Lateral Scler"},{"issue":"4","key":"1217_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jamaneurol.2019.4490","volume":"77","author":"CN Fournier","year":"2020","unstructured":"Fournier CN, et al. Development and validation of the Rasch-built overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol. 2020;77(4):480\u20138.","journal-title":"JAMA Neurol"},{"issue":"3\u20134","key":"1217_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/21678421.2022.2153607","volume":"24","author":"CN Fournier","year":"2023","unstructured":"Fournier CN, James V, Glass JD. Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(3\u20134):311\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3\u20134","key":"1217_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/21678421.2024.2320880","volume":"25","author":"A Genge","year":"2024","unstructured":"Genge A, et al. The ALSFRS-R summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25(3\u20134):382\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5\u20136","key":"1217_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/21678421.2015.1026829","volume":"16","author":"F Franchignoni","year":"2015","unstructured":"Franchignoni F, et al. A further rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5\u20136):331\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"12","key":"1217_CR39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/jnnp-2012-304701","volume":"84","author":"F Franchignoni","year":"2013","unstructured":"Franchignoni F, et al. Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1217_CR40","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1212\/01.WNL.0000144345.49510.4E","volume":"63","author":"BJ Traynor","year":"2004","unstructured":"Traynor BJ, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63(10):1933\u20135.","journal-title":"Neurology"},{"issue":"3","key":"1217_CR41","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/jnnp.2005.072660","volume":"77","author":"A Czaplinski","year":"2006","unstructured":"Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1217_CR42","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/ageing\/afq084","volume":"39","author":"SC Allen","year":"2010","unstructured":"Allen SC, et al. Performing slow vital capacity in older people with and without cognitive impairment\u2013is it useful? Age Ageing. 2010;39(5):588\u201391.","journal-title":"Age Ageing"},{"issue":"1","key":"1217_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/mus.20450","volume":"33","author":"EP Schmidt","year":"2006","unstructured":"Schmidt EP, et al. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve. 2006;33(1):127\u201332.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1217_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/02770909809075669","volume":"35","author":"SK Chhabra","year":"1998","unstructured":"Chhabra SK. Forced vital capacity, slow vital capacity, or inspiratory vital capacity: which is the best measure of vital capacity? J Asthma. 1998;35(4):361\u20135.","journal-title":"J Asthma"},{"issue":"1","key":"1217_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1378\/chest.103.1.170","volume":"103","author":"JA Fiz","year":"1993","unstructured":"Fiz JA, et al. Spirometry and maximal respiratory pressures in patients with facial paralysis. Chest. 1993;103(1):170\u20133.","journal-title":"Chest"},{"issue":"1","key":"1217_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0733-8619(18)30938-1","volume":"5","author":"PL Andres","year":"1987","unstructured":"Andres PL, et al. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin. 1987;5(1):125\u201341.","journal-title":"Neurol Clin"},{"issue":"6","key":"1217_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1212\/WNL.0000000000002941","volume":"87","author":"JM Shefner","year":"2016","unstructured":"Shefner JM, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87(6):617\u201324.","journal-title":"Neurology"},{"issue":"4","key":"1217_CR48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mus.25586","volume":"56","author":"PL Andres","year":"2017","unstructured":"Andres PL, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56(4):710\u20135.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1217_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/21678421.2012.762930","volume":"14","author":"JD Berry","year":"2013","unstructured":"Berry JD, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162\u20138.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"11","key":"1217_CR50","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","volume":"18","author":"DM Finkelstein","year":"1999","unstructured":"Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18(11):1341\u201354.","journal-title":"Stat Med"},{"issue":"1","key":"1217_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1740774509356117","volume":"7","author":"L Wittkop","year":"2010","unstructured":"Wittkop L, et al. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials. 2010;7(1):19\u201335.","journal-title":"Clin Trials"},{"issue":"3","key":"1217_CR52","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200241","volume":"11","author":"BJ Murdock","year":"2024","unstructured":"Murdock BJ, et al. Peripheral immune profiles predict ALS progression in an age- and sex-dependent manner. Neurol Neuroimmunol Neuroinflamm. 2024;11(3): e200241.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1217_CR53","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ana.26714","volume":"94","author":"M Quintana","year":"2023","unstructured":"Quintana M, et al. Design and statistical innovations in a platform trial for amyotrophic lateral sclerosis. Ann Neurol. 2023;94(3):547\u201360.","journal-title":"Ann Neurol"},{"key":"1217_CR54","unstructured":"21st Century Cures Act. Public Law 114th United States Congress. 2016."},{"issue":"1","key":"1217_CR55","first-page":"1015","volume":"1","author":"JE Broderick","year":"2013","unstructured":"Broderick JE, et al. Advances in patient-reported outcomes: the NIH PROMIS((R)) measures. EGEMS (Wash DC). 2013;1(1):1015.","journal-title":"EGEMS (Wash DC)"},{"issue":"3","key":"1217_CR56","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","volume":"21","author":"RC Gershon","year":"2012","unstructured":"Gershon RC, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21(3):475\u201386.","journal-title":"Qual Life Res"},{"issue":"6","key":"1217_CR57","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00415-020-09774-8","volume":"267","author":"F De Marchi","year":"2020","unstructured":"De Marchi F, et al. Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. J Neurol. 2020;267(6):1754\u20139.","journal-title":"J Neurol"},{"issue":"9","key":"1217_CR58","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1212\/01.wnl.0000242887.79115.19","volume":"67","author":"Z Simmons","year":"2006","unstructured":"Simmons Z, et al. The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology. 2006;67(9):1659\u201364.","journal-title":"Neurology"},{"issue":"5","key":"1217_CR59","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/mus.26203","volume":"58","author":"SH Felgoise","year":"2018","unstructured":"Felgoise SH, et al. Amyotrophic lateral sclerosis-specific quality of life-short form (ALSSQOL-SF): a brief, reliable, and valid version of the ALSSQOL-R. Muscle Nerve. 2018;58(5):646\u201354.","journal-title":"Muscle Nerve"},{"issue":"Suppl 3","key":"1217_CR60","doi-asserted-by":"publisher","first-page":"III16","DOI":"10.1007\/BF03161085","volume":"246","author":"C Jenkinson","year":"1999","unstructured":"Jenkinson C, et al. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis\/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(Suppl 3):III16\u201321.","journal-title":"J Neurol"},{"issue":"7","key":"1217_CR61","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ene.13638","volume":"25","author":"RA Smith","year":"2018","unstructured":"Smith RA, et al. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). Eur J Neurol. 2018;25(7):907-e66.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1217_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12955-022-01919-9","volume":"20","author":"SL Hartmaier","year":"2022","unstructured":"Hartmaier SL, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1217_CR63","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/mus.21765","volume":"42","author":"SW Ahn","year":"2010","unstructured":"Ahn SW, et al. Reproducibility of the motor unit number index (MUNIX) in normal controls and amyotrophic lateral sclerosis patients. Muscle Nerve. 2010;42(5):808\u201313.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1217_CR64","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mus.26339","volume":"58","author":"M Higashihara","year":"2018","unstructured":"Higashihara M, et al. Reproducibility of motor unit number index and multiple point stimulation motor unit number estimation in controls. Muscle Nerve. 2018;58(5):660\u20134.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1217_CR65","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mus.21824","volume":"42","author":"SD Nandedkar","year":"2010","unstructured":"Nandedkar SD, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010;42(5):798\u2013807.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1217_CR66","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mus.22204","volume":"44","author":"SD Nandedkar","year":"2011","unstructured":"Nandedkar SD, Barkhaus PE, Stalberg EV. Reproducibility of MUNIX in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2011;44(6):919\u201322.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1217_CR67","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.clinph.2012.01.004","volume":"123","author":"WA Boekestein","year":"2012","unstructured":"Boekestein WA, et al. Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): a direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol. 2012;123(8):1644\u20139.","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"1217_CR68","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clinph.2012.08.023","volume":"124","author":"J Furtula","year":"2013","unstructured":"Furtula J, et al. MUNIX and incremental stimulation MUNE in ALS patients and control subjects. Clin Neurophysiol. 2013;124(3):610\u20138.","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"1217_CR69","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/17482968.2012.688837","volume":"13","author":"SB Rutkove","year":"2012","unstructured":"Rutkove SB, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13(5):439\u201345.","journal-title":"Amyotroph Lateral Scler"},{"issue":"3","key":"1217_CR70","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mus.24128","volume":"49","author":"SB Rutkove","year":"2014","unstructured":"Rutkove SB, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014;49(3):441\u20133.","journal-title":"Muscle Nerve"},{"key":"1217_CR71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cnp.2018.10.002","volume":"3","author":"S Vucic","year":"2018","unstructured":"Vucic S, et al. Utility of threshold tracking transcranial magnetic stimulation in ALS. Clin Neurophysiol Pract. 2018;3:164\u201372.","journal-title":"Clin Neurophysiol Pract"},{"issue":"2","key":"1217_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","volume":"78","author":"BJ Wainger","year":"2021","unstructured":"Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186\u201396.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1217_CR73","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mus.27146","volume":"63","author":"MD Weiss","year":"2021","unstructured":"Weiss MD, et al. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: preliminary findings from a small phase II randomized controlled trial. Muscle Nerve. 2021;63(3):371\u201383.","journal-title":"Muscle Nerve"},{"issue":"7","key":"1217_CR74","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4155\/cli.14.52","volume":"4","author":"S Paganoni","year":"2014","unstructured":"Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4(7):605\u201318.","journal-title":"Clin Investig (Lond)"},{"key":"1217_CR75","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clinph.2022.02.020","volume":"137","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Baker MR, Bashford J. The landscape of neurophysiological outcome measures in ALS interventional trials: a systematic review. Clin Neurophysiol. 2022;137:132\u201341.","journal-title":"Clin Neurophysiol"},{"key":"1217_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112818","author":"MAJ van den Bos","year":"2019","unstructured":"van den Bos MAJ, et al. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112818.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1217_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.clinph.2019.07.023","volume":"131","author":"MC Kiernan","year":"2020","unstructured":"Kiernan MC, et al. Measurement of axonal excitability: consensus guidelines. Clin Neurophysiol. 2020;131(1):308\u201323.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"1217_CR78","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1212\/WNL.0000000000004761","volume":"90","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22\u201330.","journal-title":"Neurology"},{"issue":"22","key":"1217_CR79","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247\u201357.","journal-title":"Neurology"},{"issue":"7","key":"1217_CR80","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1093\/brain\/awac394","volume":"146","author":"M Benatar","year":"2023","unstructured":"Benatar M, Wuu J, Turner MR. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain. 2023;146(7):2711\u20136.","journal-title":"Brain"},{"key":"1217_CR81","unstructured":"FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. Food and Drug Administration. 2023."},{"issue":"8","key":"1217_CR82","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1217_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01126","volume":"9","author":"D Lanznaster","year":"2018","unstructured":"Lanznaster D, et al. Metabolomics biomarkers: a strategy toward therapeutics improvement in ALS. Front Neurol. 2018;9: 1126.","journal-title":"Front Neurol"},{"issue":"5","key":"1217_CR84","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","volume":"21","author":"SA Goutman","year":"2022","unstructured":"Goutman SA, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):480\u201393.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1217_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13024-023-00685-6","volume":"19","author":"KE Irwin","year":"2024","unstructured":"Irwin KE, et al. Fluid biomarkers for amyotrophic lateral sclerosis: a review. Mol Neurodegener. 2024;19(1):9.","journal-title":"Mol Neurodegener"},{"key":"1217_CR86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CLEP.S153196","volume":"10","author":"RP van Eijk","year":"2018","unstructured":"van Eijk RP, et al. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333\u201341.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"1217_CR87","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/mus.28169","volume":"70","author":"DV Neel","year":"2024","unstructured":"Neel DV, et al. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis. Muscle Nerve. 2024;70(2):232\u20139.","journal-title":"Muscle Nerve"},{"key":"1217_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050452","author":"L Tzeplaeff","year":"2024","unstructured":"Tzeplaeff L, et al. Unraveling the heterogeneity of ALS-a call to redefine patient stratification for better outcomes in clinical trials. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13050452.","journal-title":"Cells"},{"issue":"4","key":"1217_CR89","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/acn3.550","volume":"5","author":"JD Berry","year":"2018","unstructured":"Berry JD, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5(4):474\u201385.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"1217_CR90","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1212\/01.wnl.0000180717.29273.12","volume":"65","author":"JP Van den Berg","year":"2005","unstructured":"Van den Berg JP, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65(8):1264\u20137.","journal-title":"Neurology"},{"issue":"5","key":"1217_CR91","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/jnnp-2014-309601","volume":"86","author":"J Rooney","year":"2015","unstructured":"Rooney J, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry. 2015;86(5):496\u2013501.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1217_CR92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/JMDH.S205313","volume":"12","author":"AJ Paipa","year":"2019","unstructured":"Paipa AJ, et al. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in Spain: association with noninvasive mechanical ventilation. J Multidiscip Healthc. 2019;12:465\u201370.","journal-title":"J Multidiscip Healthc"},{"issue":"8","key":"1217_CR93","volume":"8","author":"A Sulistyo","year":"2023","unstructured":"Sulistyo A, et al. Enteral tube feeding for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev. 2023;8(8): CD004030.","journal-title":"Cochrane Database Syst Rev"},{"key":"1217_CR94","unstructured":"Conroy E et al. IMPACT-ALS: summary of results from a European survey of people living with ALS. Amyotroph Lateral Scler Frontotemporal Degener, 2023: p. 1-10."},{"issue":"2","key":"1217_CR95","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s13311-014-0322-x","volume":"12","author":"Z Simmons","year":"2015","unstructured":"Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics. 2015;12(2):394\u2013402.","journal-title":"Neurotherapeutics"},{"key":"1217_CR96","doi-asserted-by":"crossref","unstructured":"Bublitz SK et al. Thick mucus in ALS: a mixed-method study on associated factors and its impact on quality of life of patients and caregivers. Brain Sci, 2022;12(2):252.","DOI":"10.3390\/brainsci12020252"},{"issue":"6","key":"1217_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16264","volume":"31","author":"P Van Damme","year":"2024","unstructured":"Van Damme P, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). Eur J Neurol. 2024;31(6): e16264.","journal-title":"Eur J Neurol"},{"issue":"15","key":"1217_CR98","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227\u201333.","journal-title":"Neurology"},{"issue":"15","key":"1217_CR99","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218\u201326.","journal-title":"Neurology"},{"issue":"46","key":"1217_CR100","doi-asserted-by":"publisher","first-page":"E1453","DOI":"10.1503\/cmaj.191721","volume":"192","author":"C Shoesmith","year":"2020","unstructured":"Shoesmith C, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020;192(46):E1453\u201368.","journal-title":"CMAJ"},{"key":"1217_CR101","doi-asserted-by":"publisher","first-page":"1154579","DOI":"10.3389\/fneur.2023.1154579","volume":"14","author":"R Boostani","year":"2023","unstructured":"Boostani R, et al. Iranian clinical practice guideline for amyotrophic lateral sclerosis. Front Neurol. 2023;14:1154579.","journal-title":"Front Neurol"},{"issue":"3","key":"1217_CR102","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17482960903015986","volume":"10","author":"R Bedlack","year":"2009","unstructured":"Bedlack R, Hardiman O. ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters. Amyotroph Lateral Scler. 2009;10(3):129\u201330.","journal-title":"Amyotroph Lateral Scler"},{"key":"1217_CR103","unstructured":"ALS Untangled. [cited 2025]; Available from: https:\/\/www.alsuntangled.com\/."},{"issue":"1 Suppl","key":"1217_CR104","first-page":"101","volume":"35","author":"H Kwiecinski","year":"2001","unstructured":"Kwiecinski H, et al. The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials. Neurol Neurochir Pol. 2001;35(1 Suppl):101\u20136.","journal-title":"Neurol Neurochir Pol"},{"issue":"4","key":"1217_CR105","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17482960801900032","volume":"9","author":"RW Orrell","year":"2008","unstructured":"Orrell RW, Lane RJ, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis\/motor neuron disease. Amyotroph Lateral Scler. 2008;9(4):195\u2013211.","journal-title":"Amyotroph Lateral Scler"},{"issue":"5","key":"1217_CR106","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00702-004-0220-1","volume":"112","author":"M Graf","year":"2005","unstructured":"Graf M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna). 2005;112(5):649\u201360.","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"1217_CR107","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1753-4887.2011.00444.x","volume":"70","author":"MJ Stanger","year":"2012","unstructured":"Stanger MJ, et al. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012;70(2):107\u201317.","journal-title":"Nutr Rev"},{"issue":"14","key":"1217_CR108","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein EA, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549\u201356.","journal-title":"JAMA"},{"issue":"8","key":"1217_CR109","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/0028-3908(85)90011-5","volume":"24","author":"J Mizoule","year":"1985","unstructured":"Mizoule J, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission\u2013I. Anticonvulsant properties. Neuropharmacology. 1985;24(8):767\u201373.","journal-title":"Neuropharmacology"},{"issue":"18","key":"1217_CR110","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.2174\/092986710791163939","volume":"17","author":"BC Cheah","year":"2010","unstructured":"Cheah BC, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942\u2013199.","journal-title":"Curr Med Chem"},{"issue":"10","key":"1217_CR111","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1111\/j.1460-9568.2008.06211.x","volume":"27","author":"N Lamanauskas","year":"2008","unstructured":"Lamanauskas N, Nistri A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008;27(10):2501\u201314.","journal-title":"Eur J Neurosci"},{"issue":"1\u20132","key":"1217_CR112","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/0014-2999(94)90716-1","volume":"257","author":"J Mantz","year":"1994","unstructured":"Mantz J, et al. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol. 1994;257(1\u20132):R7-8.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"1217_CR113","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N Engl J Med. 1994;330(9):585\u201391.","journal-title":"N Engl J Med"},{"issue":"4 Suppl 2","key":"1217_CR114","first-page":"S86","volume":"47","author":"RG Miller","year":"1996","unstructured":"Miller RG, et al. Clinical trials of riluzole in patients with ALS ALS\/Riluzole Study Group-II. Neurology. 1996;47(4 Suppl 2):S86-90 (discussion S90-2).","journal-title":"Neurology"},{"key":"1217_CR115","first-page":"61","volume":"7","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61\u201370.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"3","key":"1217_CR116","volume":"2012","author":"RG Miller","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3): CD001447.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1217_CR117","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s004150200071","volume":"249","author":"G Bensimon","year":"2002","unstructured":"Bensimon G, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609\u201315.","journal-title":"J Neurol"},{"issue":"4","key":"1217_CR118","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00415-003-1026-z","volume":"250","author":"BJ Traynor","year":"2003","unstructured":"Traynor BJ, et al. An outcome study of riluzole in amyotrophic lateral sclerosis\u2013a population-based study in Ireland, 1996\u20132000. J Neurol. 2003;250(4):473\u20139.","journal-title":"J Neurol"},{"issue":"1","key":"1217_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/146608202317576499","volume":"3","author":"MR Turner","year":"2002","unstructured":"Turner MR, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):15\u201321.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"7\u20138","key":"1217_CR120","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","volume":"21","author":"JA Andrews","year":"2020","unstructured":"Andrews JA, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7\u20138):509\u201318.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"1217_CR121","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/mus.27724","volume":"66","author":"NJ Thakore","year":"2022","unstructured":"Thakore NJ, et al. Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis. Muscle Nerve. 2022;66(6):702\u20138.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1217_CR122","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","volume":"14","author":"S Zoccolella","year":"2007","unstructured":"Zoccolella S, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14(3):262\u20138.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1217_CR123","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archneur.55.4.526","volume":"55","author":"M Riviere","year":"1998","unstructured":"Riviere M, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526\u20138.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"1217_CR124","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/21678421.2019.1655060","volume":"21","author":"NJ Thakore","year":"2020","unstructured":"Thakore NJ, et al. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1\u20132):140\u20133.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1217_CR125","doi-asserted-by":"crossref","unstructured":"Casiraghi A et al. Crushing riluzole tablets: evaluation of loss of powder and active principle in a home-simulation experiment. Amyotroph Lateral Scler Frontotemporal Degener, 2023: p. 1-7.","DOI":"10.1080\/21678421.2023.2245860"},{"key":"1217_CR126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/DDDT.S123776","volume":"11","author":"AM Dyer","year":"2017","unstructured":"Dyer AM, Smith A. Riluzole 5 mg\/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug Des Devel Ther. 2017;11:59\u201364.","journal-title":"Drug Des Devel Ther"},{"key":"1217_CR127","unstructured":"Tiglutik: Prescribing Information. Food and Drug Administration. 2018."},{"key":"1217_CR128","unstructured":"Exservan: Prescribing Information. Food and Drug Administration. 2019."},{"key":"1217_CR129","unstructured":"Mitsubishi Tanabe Pharma America to discontinue Exservan (riluzole). 2024: Mitsubishi Tanabe Pharma America."},{"issue":"5","key":"1217_CR130","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000516752","volume":"55","author":"CA Brown","year":"2021","unstructured":"Brown CA, et al. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55(5):342\u201353.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"1217_CR131","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, et al. Phase 1\u20132 Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109\u201319.","journal-title":"N Engl J Med"},{"issue":"12","key":"1217_CR132","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110.","journal-title":"N Engl J Med"},{"key":"1217_CR133","unstructured":"Tofersen\/Qalsody. 2025: International Alliance of ALS\/MND Associations. https:\/\/www.als-mnd.org\/support-for-pals-cals\/approved-drugs\/tofersen-qalsody\/."},{"key":"1217_CR134","unstructured":"Health Technology assessment report: Qalsody (tofersen). 2025: Joint Nordic HTA-Bodies."},{"key":"1217_CR135","doi-asserted-by":"crossref","unstructured":"Edaravone Acute Infarction Study, G., Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15(3):222\u20139.","DOI":"10.1159\/000069318"},{"issue":"2","key":"1217_CR136","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.11.008","volume":"20","author":"Y Tsukamoto","year":"2011","unstructured":"Tsukamoto Y, et al. Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease. J Stroke Cerebrovasc Dis. 2011;20(2):111\u20136.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"1217_CR137","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.clinthera.2022.11.005","volume":"44","author":"K Zhao","year":"2022","unstructured":"Zhao K, et al. Edaravone for acute ischemic stroke: a systematic review and meta-analysis. Clin Ther. 2022;44(12):e29\u201338.","journal-title":"Clin Ther"},{"issue":"2","key":"1217_CR138","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","volume":"79","author":"S Witzel","year":"2022","unstructured":"Witzel S, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121\u201330.","journal-title":"JAMA Neurol"},{"issue":"sup1","key":"1217_CR139","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/21678421.2017.1362440","volume":"18","author":"A Kalin","year":"2017","unstructured":"Kalin A, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):71\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1217_CR140","doi-asserted-by":"crossref","unstructured":"Writing G and A.L.S.S.G. Edaravone. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7): 505\u201312.","DOI":"10.1016\/S1474-4422(17)30115-1"},{"issue":"10","key":"1217_CR141","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cpdd.952","volume":"10","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188\u201397.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"1217_CR142","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.clinthera.2023.09.025","volume":"45","author":"H Shimizu","year":"2023","unstructured":"Shimizu H, et al. Pharmacokinetics of edaravone oral suspension in patients with amyotrophic lateral sclerosis. Clin Ther. 2023;45(12):1251\u20138.","journal-title":"Clin Ther"},{"issue":"2","key":"1217_CR143","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mus.27768","volume":"67","author":"A Genge","year":"2023","unstructured":"Genge A, et al. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023;67(2):124\u20139.","journal-title":"Muscle Nerve"},{"key":"1217_CR144","unstructured":"FDA approves oral form for the treatment of adults with amyotrophic lateral sclerosis (ALS). Food and Drug Administration. 2022."},{"key":"1217_CR145","unstructured":"Mitsubishi Tanabe Pharma America presents final results from the global, phase 3b MT-1186-A02 post-marketing study of radicava (edaravone) in ALS. 2024: Mitsubishi Tanabe Pharma America."},{"key":"1217_CR146","unstructured":"Ferrer reports top-line results from Phase III ADORE study in ALS. 2025: Ferrer."},{"issue":"1","key":"1217_CR147","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2014.08.034","volume":"36","author":"PA Dionisio","year":"2015","unstructured":"Dionisio PA, et al. Amyloid-beta pathology is attenuated by tauroursodeoxycholic acid treatment in APP\/PS1 mice after disease onset. Neurobiol Aging. 2015;36(1):228\u201340.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1217_CR148","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17482960802320487","volume":"10","author":"ME Cudkowicz","year":"2009","unstructured":"Cudkowicz ME, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99\u2013106.","journal-title":"Amyotroph Lateral Scler"},{"issue":"10","key":"1217_CR149","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919\u201330.","journal-title":"N Engl J Med"},{"issue":"11","key":"1217_CR150","first-page":"786","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard A. Amylyx\u2019s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data. Nat Rev Drug Discov. 2022;21(11):786.","journal-title":"Nat Rev Drug Discov"},{"key":"1217_CR151","unstructured":"Summary review, Relyvrio. Center for Drug Evaluation and Research, Food and Drug Administration. 2022."},{"issue":"1","key":"1217_CR152","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.27091","volume":"63","author":"S Paganoni","year":"2021","unstructured":"Paganoni S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31\u20139.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1217_CR153","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","volume":"93","author":"S Paganoni","year":"2022","unstructured":"Paganoni S, et al. Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022;93(8):871\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1217_CR154","unstructured":"Pharmaceuticals A. Amylyx pharmaceuticals announces formal intention to remove relyvrio\/albrioza from the market; provides updates on access to therapy, pipeline, corporate restructuring and strategy. 2024."},{"issue":"5","key":"1217_CR155","first-page":"848","volume":"38","author":"M Kikuchi","year":"1997","unstructured":"Kikuchi M, et al. Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1997;38(5):848\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1217_CR156","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.taap.2011.01.003","volume":"251","author":"RA Hemendinger","year":"2011","unstructured":"Hemendinger RA, Armstrong EJ 3rd, Brooks BR. Methyl vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicol Appl Pharmacol. 2011;251(3):217\u201325.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1217_CR157","doi-asserted-by":"crossref","unstructured":"Group, A.L. ALSUntangled No. 30: methylcobalamin. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7\u20138):536\u20139.","DOI":"10.3109\/21678421.2015.1070574"},{"issue":"4","key":"1217_CR158","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/jnnp-2018-319294","volume":"90","author":"R Kaji","year":"2019","unstructured":"Kaji R, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II\/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019;90(4):451\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1217_CR159","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamaneurol.2022.0901","volume":"79","author":"R Oki","year":"2022","unstructured":"Oki R, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575\u201383.","journal-title":"JAMA Neurol"},{"key":"1217_CR160","unstructured":"Rozebalamin for Injection 25mg (mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis. 2024: Eisai Global."},{"issue":"sup1","key":"1217_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2024.2403293","volume":"25","author":"P Communications","year":"2024","unstructured":"Communications P. Abstract Book 35th International Symposium on ALS\/MND (Complete printable file). Amyotroph Lateral Scler Frontotemporal Degener. 2024;25(sup1):1\u201392.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"1217_CR162","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neulet.2009.10.074","volume":"468","author":"H Kim","year":"2010","unstructured":"Kim H, et al. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett. 2010;468(3):190\u20134.","journal-title":"Neurosci Lett"},{"issue":"6","key":"1217_CR163","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5966\/sctm.2014-0212","volume":"4","author":"KW Oh","year":"2015","unstructured":"Oh KW, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4(6):590\u20137.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"1217_CR164","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ana.25302","volume":"84","author":"KW Oh","year":"2018","unstructured":"Oh KW, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol. 2018;84(3):361\u201373.","journal-title":"Ann Neurol"},{"key":"1217_CR165","doi-asserted-by":"publisher","first-page":"1148444","DOI":"10.3389\/fnagi.2023.1148444","volume":"15","author":"JY Nam","year":"2023","unstructured":"Nam JY, et al. Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R(R): lenzumestrocel) treatment in ALS: propensity-score-matched control, surveillance study. Front Aging Neurosci. 2023;15:1148444.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1217_CR166","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s13063-022-06327-4","volume":"23","author":"JY Nam","year":"2022","unstructured":"Nam JY, et al. Efficacy and safety of lenzumestrocel (neuronata-R(R) inj) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials. 2022;23(1):415.","journal-title":"Trials"},{"key":"1217_CR167","unstructured":"Han-soo L. Corestem Chemon's stock plunges after failed P3 ALS drug trial. 2024: Korea Biomedical Review."},{"key":"1217_CR168","unstructured":"Drugs@FDA: FDA-Approved Drugs. Food and Drug Administration."},{"key":"1217_CR169","unstructured":"European Medicines Agency. 2025. https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"1217_CR170","unstructured":"Drug Product Database online query. Government of Canada. [cited 2025]. https:\/\/health-products.canada.ca\/dpd-bdpp\/."},{"issue":"1\u20132","key":"1217_CR171","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","volume":"21","author":"JS Mora","year":"2020","unstructured":"Mora JS, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1\u20132):5\u201314.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3\u20134","key":"1217_CR172","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/21678421.2022.2119868","volume":"24","author":"S Salomon-Zimri","year":"2023","unstructured":"Salomon-Zimri S, et al. Combination of ciprofloxacin\/celecoxib as a novel therapeutic strategy for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(3\u20134):263\u201371.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"24","key":"1217_CR173","doi-asserted-by":"publisher","first-page":"e2294","DOI":"10.1212\/WNL.0000000000008620","volume":"93","author":"JD Berry","year":"2019","unstructured":"Berry JD, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019;93(24):e2294\u2013305.","journal-title":"Neurology"},{"key":"1217_CR174","unstructured":"FDA. Update on Amyotrophic Lateral Sclerosis (ALS) Product Development. 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/update-amyotrophic-lateral-sclerosis-als-product-development."},{"issue":"4","key":"1217_CR175","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/jnr.20386","volume":"79","author":"V Calabrese","year":"2005","unstructured":"Calabrese V, et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res. 2005;79(4):509\u201321.","journal-title":"J Neurosci Res"},{"issue":"2","key":"1217_CR176","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1358863X9700200201","volume":"2","author":"PL Capecchi","year":"1997","unstructured":"Capecchi PL, et al. Carnitines increase plasma levels of adenosine and ATP in humans. Vasc Med. 1997;2(2):77\u201381.","journal-title":"Vasc Med"},{"issue":"2","key":"1217_CR177","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12640-010-9165-3","volume":"19","author":"G Nagesh-Babu","year":"2011","unstructured":"Nagesh-Babu G, Kumar A, Singh RL. Chronic pretreatment with acetyl-L-carnitine and +\/-DL-alpha-lipoic acid protects against acute glutamate-induced neurotoxicity in rat brain by altering mitochondrial function. Neurotox Res. 2011;19(2):319\u201329.","journal-title":"Neurotox Res"},{"key":"1217_CR178","doi-asserted-by":"crossref","unstructured":"Grossini E et al. Effects of acetyl-L-carnitine on oxidative stress in amyotrophic lateral sclerosis patients: evaluation on plasma markers and members of the neurovascular unit. Antioxidants (Basel). 2023;12(10).","DOI":"10.3390\/antiox12101887"},{"issue":"5\u20136","key":"1217_CR179","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/21678421.2013.764568","volume":"14","author":"E Beghi","year":"2013","unstructured":"Beghi E, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5\u20136):397\u2013405.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"11","key":"1217_CR180","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1007\/s00415-023-11844-6","volume":"270","author":"S Sassi","year":"2023","unstructured":"Sassi S, et al. Retrospective observational study on the use of acetyl-L-carnitine in ALS. J Neurol. 2023;270(11):5344\u201357.","journal-title":"J Neurol"},{"issue":"1","key":"1217_CR181","volume":"1","author":"L Ng","year":"2017","unstructured":"Ng L, et al. Symptomatic treatments for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev. 2017;1(1): CD011776.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1217_CR182","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrneurol.2016.111","volume":"12","author":"EV Hobson","year":"2016","unstructured":"Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12(9):526\u201338.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1217_CR183","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/WCO.0000000000000135","volume":"27","author":"TM Jenkins","year":"2014","unstructured":"Jenkins TM, Hollinger H, McDermott CJ. The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol. 2014;27(5):524\u201331.","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"1217_CR184","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1212\/01.WNL.0000142042.50528.2F","volume":"63","author":"BR Brooks","year":"2004","unstructured":"Brooks BR, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan\/quinidine: a randomized trial. Neurology. 2004;63(8):1364\u201370.","journal-title":"Neurology"},{"issue":"5","key":"1217_CR185","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693\u2013702.","journal-title":"Ann Neurol"},{"issue":"3","key":"1217_CR186","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","volume":"14","author":"R Smith","year":"2017","unstructured":"Smith R, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta Treatment Trial. Neurotherapeutics. 2017;14(3):762\u201372.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"1217_CR187","volume":"5","author":"E James","year":"2022","unstructured":"James E, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease\/amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2022;5(5): CD006981.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl","key":"1217_CR188","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0022-510X(96)00104-9","volume":"139","author":"AR Newall","year":"1996","unstructured":"Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS\/MND. J Neurol Sci. 1996;139(Suppl):43\u20134.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1217_CR189","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00455-011-9359-8","volume":"27","author":"K Sdravou","year":"2012","unstructured":"Sdravou K, Walshe M, Dagdilelis L. Effects of carbonated liquids on oropharyngeal swallowing measures in people with neurogenic dysphagia. Dysphagia. 2012;27(2):240\u201350.","journal-title":"Dysphagia"},{"issue":"5","key":"1217_CR190","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1152\/jn.00130.2016","volume":"116","author":"RW Mulheren","year":"2016","unstructured":"Mulheren RW, Kamarunas E, Ludlow CL. Sour taste increases swallowing and prolongs hemodynamic responses in the cortical swallowing network. J Neurophysiol. 2016;116(5):2033\u201342.","journal-title":"J Neurophysiol"},{"key":"1217_CR191","doi-asserted-by":"crossref","unstructured":"Bozorgi C, Holleufer C, Wendin K. Saliva secretion and swallowing-the impact of different types of food and drink on subsequent intake. Nutrients. 2020;12(1):256.","DOI":"10.3390\/nu12010256"},{"issue":"4","key":"1217_CR192","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mus.24892","volume":"53","author":"JB Caress","year":"2016","unstructured":"Caress JB, et al. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve. 2016;53(4):513\u20137.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1217_CR193","volume":"13","author":"SR Menakuru","year":"2021","unstructured":"Menakuru SR, et al. Disseminated intravascular coagulation due to drinking tonic water. Cureus. 2021;13(12): e20512.","journal-title":"Cureus"},{"key":"1217_CR194","unstructured":"Drug products containing quinine offered over-the-counter (OTC) for the treatment and\/or prevention of malaria. Code of Federal Regulations. 1998."},{"issue":"2","key":"1217_CR195","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/104990910402100206","volume":"21","author":"D Amtmann","year":"2004","unstructured":"Amtmann D, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004;21(2):95\u2013104.","journal-title":"Am J Hosp Palliat Care"},{"issue":"3","key":"1217_CR196","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mus.20900","volume":"37","author":"S McClelland 3rd","year":"2008","unstructured":"McClelland S 3rd, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37(3):396\u20138.","journal-title":"Muscle Nerve"},{"issue":"11","key":"1217_CR197","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/17460441.2018.1533953","volume":"13","author":"A McGown","year":"2018","unstructured":"McGown A, Stopford MJ. High-throughput drug screens for amyotrophic lateral sclerosis drug discovery. Expert Opin Drug Discov. 2018;13(11):1015\u201325.","journal-title":"Expert Opin Drug Discov"},{"issue":"8","key":"1217_CR198","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/17460441.2016.1196183","volume":"11","author":"SA Patten","year":"2016","unstructured":"Patten SA, et al. Simple animal models for amyotrophic lateral sclerosis drug discovery. Expert Opin Drug Discov. 2016;11(8):797\u2013804.","journal-title":"Expert Opin Drug Discov"},{"issue":"10494","key":"1217_CR199","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","volume":"405","author":"NA Shneider","year":"2025","unstructured":"Shneider NA, et al. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet. 2025;405(10494):2075\u201386.","journal-title":"Lancet"},{"key":"1217_CR200","unstructured":"Biogen and Ionis announce topline phase 1 study results of investigational drug in C9orf72 amyotrophic lateral sclerosis. 2022: Biogen."},{"key":"1217_CR201","unstructured":"Biogen and Ionis announce topline phase 1\/2 study results of investigational drug in amyotrophic lateral sclerosis. 2024: Biogen."},{"issue":"6637","key":"1217_CR202","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.abq5622","volume":"379","author":"MW Baughn","year":"2023","unstructured":"Baughn MW, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140\u20139.","journal-title":"Science"},{"key":"1217_CR203","doi-asserted-by":"crossref","unstructured":"Cappella M. et al. Gene therapy for ALS-A perspective. Int J Mol Sci, 2019. 20(18):4388.","DOI":"10.3390\/ijms20184388"},{"issue":"12","key":"1217_CR204","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/acn3.52234","volume":"11","author":"D Ito","year":"2024","unstructured":"Ito D, Okada K. Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2024;11(12):3054\u201363.","journal-title":"Ann Clin Transl Neurol"},{"key":"1217_CR205","doi-asserted-by":"publisher","first-page":"12","DOI":"10.12703\/b\/9-12","volume":"9","author":"LM Gittings","year":"2020","unstructured":"Gittings LM, Sattler R. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies. Fac Rev. 2020;9:12.","journal-title":"Fac Rev"},{"issue":"2","key":"1217_CR206","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40271-023-00665-4","volume":"17","author":"J Seo","year":"2024","unstructured":"Seo J, et al. Preferences of patients with amyotrophic lateral sclerosis for intrathecal drug delivery: choosing between an implanted drug-delivery device and therapeutic lumbar puncture. Patient. 2024;17(2):161\u201377.","journal-title":"Patient"},{"issue":"7006","key":"1217_CR207","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature02873","volume":"431","author":"G Meister","year":"2004","unstructured":"Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343\u20139.","journal-title":"Nature"},{"key":"1217_CR208","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87\u2013104.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"1217_CR209","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, et al. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"issue":"5","key":"1217_CR210","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/75087","volume":"6","author":"L Sun","year":"2000","unstructured":"Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med. 2000;6(5):599\u2013602.","journal-title":"Nat Med"},{"issue":"5","key":"1217_CR211","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tins.2020.03.002","volume":"43","author":"JJ Yerbury","year":"2020","unstructured":"Yerbury JJ, Farrawell NE, McAlary L. Proteome homeostasis dysfunction: a unifying principle in ALS pathogenesis. Trends Neurosci. 2020;43(5):274\u201384.","journal-title":"Trends Neurosci"},{"key":"1217_CR212","doi-asserted-by":"crossref","unstructured":"Perni M, Mannini B. Targeting protein aggregation in ALS. Biomolecules. 2024;14(10):1324.","DOI":"10.3390\/biom14101324"},{"issue":"3","key":"1217_CR213","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1007\/s12035-021-02658-6","volume":"59","author":"S Verma","year":"2022","unstructured":"Verma S, et al. Neuromuscular junction dysfunction in amyotrophic lateral sclerosis. Mol Neurobiol. 2022;59(3):1502\u201327.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1217_CR214","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov VA, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104\u201316.","journal-title":"Nat Med"},{"issue":"6","key":"1217_CR215","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00401-017-1708-8","volume":"133","author":"J Nijssen","year":"2017","unstructured":"Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):863\u201385.","journal-title":"Acta Neuropathol"},{"issue":"R1","key":"1217_CR216","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1093\/hmg\/ddq137","volume":"19","author":"C Lagier-Tourenne","year":"2010","unstructured":"Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS\/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19(R1):R46-64.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1217_CR217","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nn.2779","volume":"14","author":"M Polymenidou","year":"2011","unstructured":"Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459\u201368.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1217_CR218","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(12)70238-7","volume":"12","author":"BD Roussel","year":"2013","unstructured":"Roussel BD, et al. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 2013;12(1):105\u201318.","journal-title":"Lancet Neurol"},{"issue":"27","key":"1217_CR219","doi-asserted-by":"publisher","first-page":"23079","DOI":"10.1074\/jbc.M111.328757","volume":"287","author":"E Bentmann","year":"2012","unstructured":"Bentmann E, et al. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem. 2012;287(27):23079\u201394.","journal-title":"J Biol Chem"},{"issue":"6","key":"1217_CR220","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4062\/biomolther.2021.012","volume":"29","author":"M Valencia","year":"2021","unstructured":"Valencia M, et al. Neuronal autophagy: characteristic features and roles in neuronal pathophysiology. Biomol Ther (Seoul). 2021;29(6):605\u201314.","journal-title":"Biomol Ther (Seoul)"},{"issue":"2","key":"1217_CR221","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11481-021-09990-7","volume":"16","author":"KL Lakpa","year":"2021","unstructured":"Lakpa KL, et al. Lysosomal stress response (LSR): physiological importance and pathological relevance. J Neuroimmune Pharmacol. 2021;16(2):219\u201337.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"12","key":"1217_CR222","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.15252\/embj.201593350","volume":"35","author":"C Sellier","year":"2016","unstructured":"Sellier C, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 2016;35(12):1276\u201397.","journal-title":"EMBO J"},{"issue":"4","key":"1217_CR223","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","volume":"186","author":"ST Hung","year":"2023","unstructured":"Hung ST, et al. PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Cell. 2023;186(4):786\u2013802 (e28).","journal-title":"Cell"},{"key":"1217_CR224","doi-asserted-by":"crossref","unstructured":"Marlin E et al. The role and therapeutic potential of the integrated stress response in amyotrophic lateral sclerosis. Int J Mol Sci. 2022;23(14):7823.","DOI":"10.3390\/ijms23147823"},{"issue":"10","key":"1217_CR225","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, et al. The integrated stress response. EMBO Rep. 2016;17(10):1374\u201395.","journal-title":"EMBO Rep"},{"issue":"10","key":"1217_CR226","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1172\/JCI0216784","volume":"110","author":"D Ron","year":"2002","unstructured":"Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest. 2002;110(10):1383\u20138.","journal-title":"J Clin Invest"},{"issue":"7462","key":"1217_CR227","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature12355","volume":"500","author":"IB Lomakin","year":"2013","unstructured":"Lomakin IB, Steitz TA. The initiation of mammalian protein synthesis and mRNA scanning mechanism. Nature. 2013;500(7462):307\u201311.","journal-title":"Nature"},{"issue":"7","key":"1217_CR228","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1083\/jcb.201702058","volume":"216","author":"PM Quiros","year":"2017","unstructured":"Quiros PM, et al. Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. J Cell Biol. 2017;216(7):2027\u201345.","journal-title":"J Cell Biol"},{"issue":"5","key":"1217_CR229","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1083\/jcb.153.5.1011","volume":"153","author":"I Novoa","year":"2001","unstructured":"Novoa I, et al. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153(5):1011\u201322.","journal-title":"J Cell Biol"},{"issue":"1","key":"1217_CR230","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41467-017-02200-0","volume":"8","author":"KM Green","year":"2017","unstructured":"Green KM, et al. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. 2017;8(1):2005.","journal-title":"Nat Commun"},{"issue":"6025","key":"1217_CR231","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.1201396","volume":"332","author":"P Tsaytler","year":"2011","unstructured":"Tsaytler P, et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332(6025):91\u20134.","journal-title":"Science"},{"issue":"Pt 12","key":"1217_CR232","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1093\/brain\/awm190","volume":"130","author":"EV Ilieva","year":"2007","unstructured":"Ilieva EV, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130(Pt 12):3111\u201323.","journal-title":"Brain"},{"issue":"5","key":"1217_CR233","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00401-018-1933-9","volume":"137","author":"ME McCauley","year":"2019","unstructured":"McCauley ME, Baloh RH. Inflammation in ALS\/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715\u201330.","journal-title":"Acta Neuropathol"},{"key":"1217_CR234","doi-asserted-by":"crossref","unstructured":"Mifflin L et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2021;118(13):e2025102118.","DOI":"10.1073\/pnas.2025102118"},{"issue":"1","key":"1217_CR235","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19\u201333.","journal-title":"Nat Rev Neurosci"},{"key":"1217_CR236","doi-asserted-by":"crossref","unstructured":"Olesen MN et al. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e697.","DOI":"10.1212\/NXI.0000000000000697"},{"key":"1217_CR237","doi-asserted-by":"crossref","unstructured":"Kallstig E, McCabe BD and Schneider BL. The links between ALS and NF-kappaB. Int J Mol Sci. 2021;22(8):3875.","DOI":"10.3390\/ijms22083875"},{"issue":"5","key":"1217_CR238","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","volume":"81","author":"AE Frakes","year":"2014","unstructured":"Frakes AE, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009\u201323.","journal-title":"Neuron"},{"key":"1217_CR239","doi-asserted-by":"crossref","unstructured":"Fomin V et al. The C9ORF72 gene, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, encodes a protein that functions in control of endothelin and glutamate signaling. Mol Cell Biol. 2018;38(22):e00155-18.","DOI":"10.1128\/MCB.00155-18"},{"issue":"9","key":"1217_CR240","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nbt.1957","volume":"29","author":"AM Haidet-Phillips","year":"2011","unstructured":"Haidet-Phillips AM, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824\u20138.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1217_CR241","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","volume":"40","author":"J Xue","year":"2014","unstructured":"Xue J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274\u201388.","journal-title":"Immunity"},{"issue":"1","key":"1217_CR242","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","volume":"237","author":"B Liao","year":"2012","unstructured":"Liao B, et al. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):147\u201352.","journal-title":"Exp Neurol"},{"key":"1217_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113259","volume":"328","author":"Y Du","year":"2020","unstructured":"Du Y, et al. Increased activation ability of monocytes from ALS patients. Exp Neurol. 2020;328: 113259.","journal-title":"Exp Neurol"},{"key":"1217_CR244","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.nicl.2015.01.009","volume":"7","author":"NR Zurcher","year":"2015","unstructured":"Zurcher NR, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409\u201314.","journal-title":"Neuroimage Clin"},{"key":"1217_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.890958","volume":"14","author":"W Yu","year":"2022","unstructured":"Yu W, et al. Neuroimmune crosstalk between the peripheral and the central immune system in amyotrophic lateral sclerosis. Front Aging Neurosci. 2022;14: 890958.","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"1217_CR246","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/bph.15802","volume":"179","author":"Y Pan","year":"2022","unstructured":"Pan Y, Nicolazzo JA. Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety. Br J Pharmacol. 2022;179(11):2577\u201388.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1217_CR247","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40478-021-01244-0","volume":"9","author":"S Waters","year":"2021","unstructured":"Waters S, et al. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS. Acta Neuropathol Commun. 2021;9(1):144.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1217_CR248","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-012-1039-8","volume":"125","author":"EA Winkler","year":"2013","unstructured":"Winkler EA, et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111\u201320.","journal-title":"Acta Neuropathol"},{"key":"1217_CR249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2013.05.047","volume":"1524","author":"C Pieper","year":"2013","unstructured":"Pieper C, Pieloch P, Galla HJ. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res. 2013;1524:1\u201311.","journal-title":"Brain Res"},{"issue":"3\u20134","key":"1217_CR250","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000522078","volume":"21","author":"Q Sun","year":"2021","unstructured":"Sun Q, et al. Inflammatory cytokine levels in patients with sporadic amyotrophic lateral sclerosis. Neurodegener Dis. 2021;21(3\u20134):87\u201392.","journal-title":"Neurodegener Dis"},{"issue":"5","key":"1217_CR251","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/WCO.0000000000000983","volume":"34","author":"SH Appel","year":"2021","unstructured":"Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr Opin Neurol. 2021;34(5):765\u201372.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"1217_CR252","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/ana.10805","volume":"55","author":"JS Henkel","year":"2004","unstructured":"Henkel JS, et al. Presence of dendritic cells, MCP-1, and activated microglia\/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221\u201335.","journal-title":"Ann Neurol"},{"issue":"3","key":"1217_CR253","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.nbd.2012.07.008","volume":"48","author":"W Zhao","year":"2012","unstructured":"Zhao W, et al. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012;48(3):418\u201328.","journal-title":"Neurobiol Dis"},{"key":"1217_CR254","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos TS, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035.","journal-title":"Front Immunol"},{"issue":"3","key":"1217_CR255","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00401-016-1548-y","volume":"132","author":"L Zondler","year":"2016","unstructured":"Zondler L, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132(3):391\u2013411.","journal-title":"Acta Neuropathol"},{"key":"1217_CR256","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-2094-10-119","volume":"10","author":"JD Lee","year":"2013","unstructured":"Lee JD, et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2013;10:119.","journal-title":"J Neuroinflammation"},{"issue":"1\u20132","key":"1217_CR257","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jns.2015.09.011","volume":"358","author":"R Spataro","year":"2015","unstructured":"Spataro R, et al. Plasma cortisol level in amyotrophic lateral sclerosis. J Neurol Sci. 2015;358(1\u20132):282\u20136.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1217_CR258","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1515\/HMBCI.2011.006","volume":"6","author":"GG Monachelli","year":"2011","unstructured":"Monachelli GG, et al. Progesterone and cortisol levels in sporadic amyotrophic lateral sclerosis (sALS): correlation with prognostic factors. Horm Mol Biol Clin Investig. 2011;6(1):167\u201373.","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1217_CR259","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neuroscience.2018.05.042","volume":"384","author":"M Meyer","year":"2018","unstructured":"Meyer M, et al. The selective glucocorticoid receptor modulator cort 113176 reduces neurodegeneration and neuroinflammation in wobbler mice spinal cord. Neuroscience. 2018;384:384\u201396.","journal-title":"Neuroscience"},{"key":"1217_CR260","doi-asserted-by":"crossref","unstructured":"Murdock BJ et al. Amyotrophic lateral sclerosis survival associates with neutrophils in a sex-specific manner. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e953.","DOI":"10.1212\/NXI.0000000000000953"},{"key":"1217_CR261","doi-asserted-by":"crossref","unstructured":"Murdock BJ et al. In vitro modeling of natural killer cell cytotoxicity to inform personalized ALS therapeutics. Ann Clin Transl Neurol. 2025;0:1\u20139.","DOI":"10.1002\/acn3.70127"},{"key":"1217_CR262","doi-asserted-by":"crossref","unstructured":"Murdock BJ et al. Early immune system changes in amyotrophic lateral sclerosis correlate with later disease progression. Medicine. 2025;6(8):100673.","DOI":"10.1016\/j.medj.2025.100673"},{"key":"1217_CR263","unstructured":"Murdock BJ et al. NK cells associate with ALS in a sex- and age-dependent manner. JCI Insight 2021;6(11):e147129."},{"key":"1217_CR264","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773288","volume":"13","author":"C Figueroa-Romero","year":"2022","unstructured":"Figueroa-Romero C, et al. Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis. Front Immunol. 2022;13: 773288.","journal-title":"Front Immunol"},{"issue":"6","key":"1217_CR265","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1073\/pnas.36.6.344","volume":"36","author":"CB Mc","year":"1950","unstructured":"Mc CB. The origin and behavior of mutable loci in maize. Proc Natl Acad Sci U S A. 1950;36(6):344\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1217_CR266","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13311-022-01233-8","volume":"19","author":"W Li","year":"2022","unstructured":"Li W, et al. Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis. Neurotherapeutics. 2022;19(4):1085\u2013101.","journal-title":"Neurotherapeutics"},{"issue":"307","key":"1217_CR267","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1126\/scitranslmed.aac8201","volume":"7","author":"W Li","year":"2015","unstructured":"Li W, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307\u2013153.","journal-title":"Sci Transl Med"},{"key":"1217_CR268","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fneur.2019.00835","volume":"10","author":"F Gouel","year":"2019","unstructured":"Gouel F, et al. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates. Front Neurol. 2019;10:835.","journal-title":"Front Neurol"},{"key":"1217_CR269","first-page":"32","volume":"4","author":"A Henriques","year":"2010","unstructured":"Henriques A, Pitzer C, Schneider A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci. 2010;4:32.","journal-title":"Front Neurosci"},{"issue":"6","key":"1217_CR270","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2019.1627324","volume":"28","author":"SA Goutman","year":"2019","unstructured":"Goutman SA, et al. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs. 2019;28(6):525\u201343.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1217_CR271","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/acn3.567","volume":"5","author":"SA Goutman","year":"2018","unstructured":"Goutman SA, et al. Long-term phase 1\/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018;5(6):730\u201340.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1217_CR272","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/stem.1628","volume":"32","author":"JS Lunn","year":"2014","unstructured":"Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014;32(5):1099\u2013109.","journal-title":"Stem Cells"},{"key":"1217_CR273","doi-asserted-by":"publisher","first-page":"5021694","DOI":"10.1155\/2020\/5021694","volume":"2020","author":"T Cunha-Oliveira","year":"2020","unstructured":"Cunha-Oliveira T, et al. Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. 2020;2020:5021694.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1217_CR274","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","volume":"417","author":"MP Murphy","year":"2009","unstructured":"Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1\u201313.","journal-title":"Biochem J"},{"issue":"7\u20138","key":"1217_CR275","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.exger.2010.01.003","volume":"45","author":"MD Brand","year":"2010","unstructured":"Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol. 2010;45(7\u20138):466\u201372.","journal-title":"Exp Gerontol"},{"key":"1217_CR276","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.neubiorev.2016.06.031","volume":"68","author":"RS Ray","year":"2016","unstructured":"Ray RS, Katyal A. Myeloperoxidase: bridging the gap in neurodegeneration. Neurosci Biobehav Rev. 2016;68:611\u201320.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"1217_CR277","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5539\/gjhs.v6n5p87","volume":"6","author":"AA Khan","year":"2014","unstructured":"Khan AA, et al. Biochemical and pathological studies on peroxidases -an updated review. Glob J Health Sci. 2014;6(5):87\u201398.","journal-title":"Glob J Health Sci"},{"key":"1217_CR278","doi-asserted-by":"crossref","unstructured":"Park HR and Yang EJ. Oxidative stress as a therapeutic target in amyotrophic lateral sclerosis: opportunities and limitations. Diagnostics (Basel). 2021;11(9):1546.","DOI":"10.3390\/diagnostics11091546"},{"issue":"1","key":"1217_CR279","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-022-00322-0","volume":"11","author":"I Agrawal","year":"2022","unstructured":"Agrawal I, et al. Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine. Transl Neurodegener. 2022;11(1):48.","journal-title":"Transl Neurodegener"},{"issue":"4","key":"1217_CR280","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mus.27672","volume":"66","author":"M Yerton","year":"2022","unstructured":"Yerton M, et al. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor. Muscle Nerve. 2022;66(4):421\u20135.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1217_CR281","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0896-6273(00)80600-5","volume":"21","author":"R Robitaille","year":"1998","unstructured":"Robitaille R. Modulation of synaptic efficacy and synaptic depression by glial cells at the frog neuromuscular junction. Neuron. 1998;21(4):847\u201355.","journal-title":"Neuron"},{"issue":"5","key":"1217_CR282","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/mus.20147","volume":"30","author":"D Jillapalli","year":"2004","unstructured":"Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects. Muscle Nerve. 2004;30(5):578\u201384.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1217_CR283","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.expneurol.2003.10.004","volume":"185","author":"LR Fischer","year":"2004","unstructured":"Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232\u201340.","journal-title":"Exp Neurol"},{"key":"1217_CR284","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-7-10","volume":"7","author":"R Xia","year":"2012","unstructured":"Xia R, et al. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol Neurodegener. 2012;7:10.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1217_CR285","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177005","volume":"12","author":"S Dzieciolowska","year":"2017","unstructured":"Dzieciolowska S, Drapeau P, Armstrong GAB. Augmented quantal release of acetylcholine at the vertebrate neuromuscular junction following tdp-43 depletion. PLoS\u00a0One. 2017;12(5): e0177005.","journal-title":"PLoS\u00a0One"},{"key":"1217_CR286","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fnmol.2016.00160","volume":"9","author":"ML Campanari","year":"2016","unstructured":"Campanari ML, et al. Neuromuscular junction impairment in amyotrophic lateral sclerosis: reassessing the role of acetylcholinesterase. Front Mol Neurosci. 2016;9:160.","journal-title":"Front Mol Neurosci"},{"issue":"13","key":"1217_CR287","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111001","volume":"39","author":"KL Krus","year":"2022","unstructured":"Krus KL, et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep. 2022;39(13): 111001.","journal-title":"Cell Rep"},{"issue":"2","key":"1217_CR288","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/01913129809032266","volume":"22","author":"T Yoshihara","year":"1998","unstructured":"Yoshihara T, et al. Ultrastructural and histochemical study of the motor end plates of the intrinsic laryngeal muscles in amyotrophic lateral sclerosis. Ultrastruct Pathol. 1998;22(2):121\u20136.","journal-title":"Ultrastruct Pathol"},{"issue":"Pt A","key":"1217_CR289","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchemneu.2016.03.003","volume":"76","author":"JA Clark","year":"2016","unstructured":"Clark JA, et al. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Chem Neuroanat. 2016;76(Pt A):35\u201347.","journal-title":"J Chem Neuroanat"},{"key":"1217_CR290","doi-asserted-by":"crossref","unstructured":"Cappello V and Francolini M. Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int J Mol Sci. 2017;18(10):2092.","DOI":"10.3390\/ijms18102092"},{"issue":"11","key":"1217_CR291","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1093\/brain\/awad202","volume":"146","author":"JM Shefner","year":"2023","unstructured":"Shefner JM, et al. Skeletal muscle in amyotrophic lateral sclerosis. Brain. 2023;146(11):4425\u201336.","journal-title":"Brain"},{"key":"1217_CR292","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fnins.2014.00252","volume":"8","author":"EB Moloney","year":"2014","unstructured":"Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci. 2014;8:252.","journal-title":"Front Neurosci"},{"issue":"4","key":"1217_CR293","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1007\/s13311-021-01143-1","volume":"18","author":"L Trujillo-Estrada","year":"2021","unstructured":"Trujillo-Estrada L, et al. SPG302 reverses synaptic and cognitive deficits without altering amyloid or tau pathology in a transgenic model of Alzheimer\u2019s disease. Neurotherapeutics. 2021;18(4):2468\u201383.","journal-title":"Neurotherapeutics"},{"key":"1217_CR294","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fphar.2019.00883","volume":"10","author":"A Bouscary","year":"2019","unstructured":"Bouscary A, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019;10:883.","journal-title":"Front Pharmacol"},{"key":"1217_CR295","doi-asserted-by":"crossref","unstructured":"Guo K et al. Longitudinal metabolomics in amyotrophic lateral sclerosis implicates impaired lipid metabolism. Ann Neurol. 2025;98(1):19\u201334.","DOI":"10.1002\/ana.27208"},{"issue":"2","key":"1217_CR296","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/brain\/awad306","volume":"147","author":"K Guo","year":"2024","unstructured":"Guo K, et al. Gut microbiome correlates with plasma lipids in amyotrophic lateral sclerosis. Brain. 2024;147(2):665\u201379.","journal-title":"Brain"},{"issue":"3","key":"1217_CR297","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/mus.27744","volume":"67","author":"SA Goutman","year":"2023","unstructured":"Goutman SA, et al. Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles. Muscle Nerve. 2023;67(3):208\u201316.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1217_CR298","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1093\/brain\/awac025","volume":"145","author":"SA Goutman","year":"2022","unstructured":"Goutman SA, et al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain. 2022;145(12):4425\u201339.","journal-title":"Brain"},{"issue":"12","key":"1217_CR299","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1136\/jnnp-2020-323611","volume":"91","author":"SA Goutman","year":"2020","unstructured":"Goutman SA, et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020;91(12):1329\u201338.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1217_CR300","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/WCO.0000000000001164","volume":"36","author":"T Burg","year":"2023","unstructured":"Burg T, Van Den Bosch L. Abnormal energy metabolism in ALS: a key player? Curr Opin Neurol. 2023;36(4):338\u201345.","journal-title":"Curr Opin Neurol"},{"key":"1217_CR301","doi-asserted-by":"publisher","first-page":"7821672","DOI":"10.1155\/2017\/7821672","volume":"2017","author":"A Ferri","year":"2017","unstructured":"Ferri A, Coccurello R. What is \u201cHyper\u201d in the ALS hypermetabolism? Mediators Inflamm. 2017;2017:7821672.","journal-title":"Mediators Inflamm"},{"issue":"9934","key":"1217_CR302","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(14)60222-1","volume":"383","author":"AM Wills","year":"2014","unstructured":"Wills AM, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065\u201372.","journal-title":"Lancet"},{"issue":"6","key":"1217_CR303","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.beem.2012.05.003","volume":"26","author":"LD Osellame","year":"2012","unstructured":"Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26(6):711\u201323.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"1217_CR304","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/bph.15738","volume":"179","author":"S Scaricamazza","year":"2022","unstructured":"Scaricamazza S, et al. Repurposing of trimetazidine for amyotrophic lateral sclerosis: a study in SOD1(G93A) mice. Br J Pharmacol. 2022;179(8):1732\u201352.","journal-title":"Br J Pharmacol"},{"key":"1217_CR305","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-physiol-021115-105045","volume":"78","author":"SM Houten","year":"2016","unstructured":"Houten SM, et al. The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders. Annu Rev Physiol. 2016;78:23\u201344.","journal-title":"Annu Rev Physiol"},{"issue":"1\u20132","key":"1217_CR306","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2009.09.029","volume":"288","author":"MJ Strong","year":"2010","unstructured":"Strong MJ. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2010;288(1\u20132):1\u201312.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1217_CR307","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2020.03.011","volume":"78","author":"M Corley","year":"2020","unstructured":"Corley M, Burns MC, Yeo GW. How RNA-binding proteins interact with RNA: molecules and mechanisms. Mol Cell. 2020;78(1):9\u201329.","journal-title":"Mol Cell"},{"key":"1217_CR308","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fgene.2018.00712","volume":"9","author":"Z Butti","year":"2018","unstructured":"Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2018;9:712.","journal-title":"Front Genet"},{"issue":"2","key":"1217_CR309","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41593-017-0047-3","volume":"21","author":"CC Chou","year":"2018","unstructured":"Chou CC, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS\/FTD. Nat Neurosci. 2018;21(2):228\u201339.","journal-title":"Nat Neurosci"},{"issue":"4","key":"1217_CR310","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.cell.2018.03.025","volume":"173","author":"K Zhang","year":"2018","unstructured":"Zhang K, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(4):958\u201371 (e17).","journal-title":"Cell"},{"key":"1217_CR311","doi-asserted-by":"crossref","unstructured":"Arnold FJ et al. Revisiting glutamate excitotoxicity in amyotrophic lateral sclerosis and age-related neurodegeneration. Int J Mol Sci. 2024;25(11):5587.","DOI":"10.3390\/ijms25115587"},{"issue":"11\u201312","key":"1217_CR312","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbadis.2006.05.002","volume":"1762","author":"L Van Den Bosch","year":"2006","unstructured":"Van Den Bosch L, et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11\u201312):1068\u201382.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1217_CR313","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1099800418784202","volume":"20","author":"ML Wright","year":"2018","unstructured":"Wright ML, et al. Potential Role of the gut microbiome in ALS: a systematic review. Biol Res Nurs. 2018;20(5):513\u201321.","journal-title":"Biol Res Nurs"},{"key":"1217_CR314","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3389\/fmicb.2016.01479","volume":"7","author":"X Fang","year":"2016","unstructured":"Fang X, et al. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 2016;7:1479.","journal-title":"Front Microbiol"},{"key":"1217_CR315","doi-asserted-by":"crossref","unstructured":"Wu S et al. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4): e12356.","DOI":"10.14814\/phy2.12356"},{"issue":"2","key":"1217_CR316","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2016.12.014","volume":"39","author":"YG Zhang","year":"2017","unstructured":"Zhang YG, et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017;39(2):322\u201336.","journal-title":"Clin Ther"},{"key":"1217_CR317","unstructured":"In Living with ALS, J. Alper, R.A. English, and A.I. Leshner, Editors. 2024: Washington (DC)."},{"issue":"2","key":"1217_CR318","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1474-4422(24)00523-4","volume":"24","author":"EL Feldman","year":"2025","unstructured":"Feldman EL, et al. Transforming amyotrophic lateral sclerosis into a liveable disease. Lancet Neurol. 2025;24(2):100\u20131.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1217_CR319","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12553-023-00738-2","volume":"13","author":"S Askin","year":"2023","unstructured":"Askin S, et al. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol (Berl). 2023;13(2):203\u201313.","journal-title":"Health Technol (Berl)"},{"issue":"1","key":"1217_CR320","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, et al. Artificial intelligence in drug development. Nat Med. 2025;31(1):45\u201359.","journal-title":"Nat Med"},{"key":"1217_CR321","doi-asserted-by":"crossref","unstructured":"Behler A et al. Diffusion tensor imaging in amyotrophic lateral sclerosis: machine learning for biomarker development. Int J Mol Sci. 2023;24(3):1911.","DOI":"10.3390\/ijms24031911"},{"issue":"1","key":"1217_CR322","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s40478-023-01686-8","volume":"11","author":"H Marriott","year":"2023","unstructured":"Marriott H, et al. Unsupervised machine learning identifies distinct ALS molecular subtypes in post-mortem motor cortex and blood expression data. Acta Neuropathol Commun. 2023;11(1):208.","journal-title":"Acta Neuropathol Commun"},{"key":"1217_CR323","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2021.103771","volume":"117","author":"H Liu","year":"2021","unstructured":"Liu H, et al. A knowledge base of clinical trial eligibility criteria. J Biomed Inform. 2021;117: 103771.","journal-title":"J Biomed Inform"},{"issue":"5","key":"1217_CR324","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2589-7500(21)00274-0","volume":"4","author":"F Faghri","year":"2022","unstructured":"Faghri F, et al. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. Lancet Digit Health. 2022;4(5):e359\u201369.","journal-title":"Lancet Digit Health"},{"key":"1217_CR325","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2023.102588","volume":"142","author":"E Tavazzi","year":"2023","unstructured":"Tavazzi E, et al. Artificial intelligence and statistical methods for stratification and prediction of progression in amyotrophic lateral sclerosis: a systematic review. Artif Intell Med. 2023;142: 102588.","journal-title":"Artif Intell Med"},{"issue":"3","key":"1217_CR326","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.21245","volume":"39","author":"JG Rabkin","year":"2009","unstructured":"Rabkin JG, et al. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009;39(3):297\u2013303.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1217_CR327","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","volume":"20","author":"A Bilbao","year":"2022","unstructured":"Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259.","journal-title":"BMC Med"},{"issue":"1","key":"1217_CR328","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/082585979401000105","volume":"10","author":"K Nelson","year":"1994","unstructured":"Nelson K, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10(1):14\u20138.","journal-title":"J Palliat Care"},{"issue":"4","key":"1217_CR329","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/neurosci5040032","volume":"5","author":"B Sevriev","year":"2024","unstructured":"Sevriev B, et al. Trehalose: neuroprotective effects and mechanisms\u2014An updated review. NeuroSci. 2024;5(4):429\u201344.","journal-title":"NeuroSci"},{"key":"1217_CR330","unstructured":"Mixed results announced for trehalose in ALS study. 2024: Medical Professionals Reference."},{"issue":"4","key":"1217_CR331","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4161\/auto.5923","volume":"4","author":"F Fornai","year":"2008","unstructured":"Fornai F, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy. 2008;4(4):527\u201330.","journal-title":"Autophagy"},{"issue":"2","key":"1217_CR332","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/mus.21423","volume":"40","author":"L Pasquali","year":"2009","unstructured":"Pasquali L, et al. Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40(2):173\u201394.","journal-title":"Muscle Nerve"},{"key":"1217_CR333","doi-asserted-by":"crossref","unstructured":"Shi Y et al. Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight. 2019;5(15):e127736.","DOI":"10.1172\/jci.insight.127736"},{"issue":"1","key":"1217_CR334","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/27694127.2022.2082201","volume":"1","author":"J Hasegawa","year":"2022","unstructured":"Hasegawa J, Inoki K, Weisman LS. PIKFYVE-dependent regulation of MTORC1 and TFEB. Autophagy Reports. 2022;1(1):247\u201351.","journal-title":"Autophagy Reports"},{"issue":"9","key":"1217_CR335","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/brain\/awae109","volume":"147","author":"S Babu","year":"2024","unstructured":"Babu S, et al. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial. Brain. 2024;147(9):2998\u20133008.","journal-title":"Brain"},{"issue":"15_supplement","key":"1217_CR336","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1212\/WNL.96.15_supplement.4484","volume":"96","author":"A Genge","year":"2021","unstructured":"Genge A, et al. A phase 1, multicenter, open label, single-ascending dose study to evaluate safety, tolerability, and pharmacokinetics of AP-101 in familial and sporadic amyotrophic lateral sclerosis (ALS) (4484). Neurology. 2021;96(15_supplement):4484.","journal-title":"Neurology"},{"key":"1217_CR337","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Gonz\u00e1lez L et al. Tideglusib, a non-ATP competitive inhibitor of GSK-3\u03b2 as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22(16):8975.","DOI":"10.3390\/ijms22168975"},{"key":"1217_CR338","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101707","volume":"53","author":"K Imamura","year":"2022","unstructured":"Imamura K, et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): a multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine. 2022;53: 101707.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1217_CR339","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hum.2015.122","volume":"27","author":"F Borel","year":"2016","unstructured":"Borel F, et al. Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther. 2016;27(1):19\u201331.","journal-title":"Hum Gene Ther"},{"key":"1217_CR340","unstructured":"Benefits of repurposed monepantel for ALS sustained for up to 2 years. 2024: ALS News Today."},{"key":"1217_CR341","unstructured":"Ractigen announces positive clinical data for RAG-17 in ALS-SOD1 treatment from investigator-initiated trial. 2024: Ractigen Therapeutics."},{"issue":"12","key":"1217_CR342","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.chembiol.2019.10.005","volume":"26","author":"PH Bos","year":"2019","unstructured":"Bos PH, et al. Development of MAP4 kinase inhibitors as motor neuron-protecting agents. Cell Chem Biol. 2019;26(12):1703\u201315 (e37).","journal-title":"Cell Chem Biol"},{"key":"1217_CR343","unstructured":"Calico provides update on fosigotifator in HEALEY ALS platform trial. 2025: Calico Life Sciences LLC."},{"key":"1217_CR344","unstructured":"DNL343 falls short of primary end point in phase 2\/3 HEALEY-ALS platform trial. 2025: Neurology Live."},{"issue":"1","key":"1217_CR345","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41467-017-02200-0","volume":"8","author":"KM Green","year":"2017","unstructured":"Green KM, et al. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Comm. 2017;8(1):2005.","journal-title":"Nat Comm"},{"key":"1217_CR346","unstructured":"InFlectis BioScience awarded $943,000 grant from the ALS association to advance ongoing ALS clinical trial with the support of IRCCS Carlo Besta Neurological Institute. 2024: Yahoo Finance."},{"issue":"8","key":"1217_CR347","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"JD Lee","year":"2017","unstructured":"Lee JD, et al. Pharmacological inhibition of complement C5a\u2013C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Br J Pharmacol. 2017;174(8):689\u201399.","journal-title":"Br J Pharmacol"},{"key":"1217_CR348","doi-asserted-by":"crossref","unstructured":"BK B et al. Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model. Human Mol Gen. 2019;28(19):3175\u201387.","DOI":"10.1093\/hmg\/ddz118"},{"key":"1217_CR349","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molimm.2018.06.007","volume":"102","author":"A-L Kj\u00e6ldgaard","year":"2018","unstructured":"Kj\u00e6ldgaard A-L, et al. Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. Mol Immunol. 2018;102:14\u201325.","journal-title":"Mol Immunol"},{"issue":"7\u20138","key":"1217_CR350","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","volume":"20","author":"J Gold","year":"2019","unstructured":"Gold J, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7\u20138):595\u2013604.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"1217_CR351","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamaneurol.2018.0035","volume":"75","author":"RK Sheean","year":"2018","unstructured":"Sheean RK, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75(6):681\u20139.","journal-title":"JAMA Neurol"},{"issue":"7\u20138","key":"1217_CR352","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/21678421.2014.951940","volume":"15","author":"RG Miller","year":"2014","unstructured":"Miller RG, et al. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7\u20138):601\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1217_CR353","unstructured":"Neuvivo seeks FDA approval for its breakthrough ALS treatment NP001. 2024: Neuvivo."},{"issue":"1","key":"1217_CR354","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152\u201372.","journal-title":"Immunol Rev"},{"key":"1217_CR355","unstructured":"Eledon announces positive topline results from phase 2a trial of tegoprubart demonstrating safety, target engagement, and biomarker response in patients living with amyotrophic lateral sclerosis. 2022: Biospace."},{"key":"1217_CR356","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2019.00362","volume":"10","author":"SM Carpanini","year":"2019","unstructured":"Carpanini SM, Torvell M, Morgan BP. Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol. 2019;10:362.","journal-title":"Front Immunol"},{"issue":"46","key":"1217_CR357","doi-asserted-by":"publisher","first-page":"E4385","DOI":"10.1073\/pnas.1318309110","volume":"110","author":"CS Lobsiger","year":"2013","unstructured":"Lobsiger CS, et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci. 2013;110(46):E4385\u201392.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1217_CR358","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1217_CR359","unstructured":"Zydus cleared to begin US trial of oral therapy usnoflast for ALS, in Phase 2b trial to involve 210 patients, company says. 2025: ALS News Today."},{"key":"1217_CR360","unstructured":"TPN-101. 2024: AlzForum therapeutics databases."},{"key":"1217_CR361","unstructured":"TPN-101 Demonstrates disease-modifying effects on C9orf72-Related ALS\/FTD. 2024: Neurology Live."},{"issue":"2","key":"1217_CR362","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bph.12277","volume":"170","author":"M Takata","year":"2013","unstructured":"Takata M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170(2):341\u201351.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1217_CR363","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/35070009","volume":"3","author":"ML Coleman","year":"2001","unstructured":"Coleman ML, et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001;3(4):339\u201345.","journal-title":"Nat Cell Biol"},{"key":"1217_CR364","doi-asserted-by":"crossref","unstructured":"Lee DH et al. ROCK and PDE-5 Inhibitors for the treatment of dementia: literature review and meta-analysis. Biomedicines 2022;10(6).","DOI":"10.3390\/biomedicines10061348"},{"key":"1217_CR365","doi-asserted-by":"crossref","unstructured":"Guan G et al. Effect of the rho-kinase\/ROCK signaling pathway on cytoskeleton components. Genes (Basel). 2023;14(2):272.","DOI":"10.3390\/genes14020272"},{"key":"1217_CR366","unstructured":"Fasudil safe, preserves motor neurons in early-stage ALS: Study, in Raya also developed a version of drug for patients with difficulty swallowing. 2024: ALS News Today."},{"key":"1217_CR367","unstructured":"Donaldson K, J.C., Hunt HJ. Safety, pharmacokinetics, and pharmacodynamics of the selective glucocorticoid receptor modulator dazucorilant in healthy volunteers. in ENCALS. 2023. Barcelona"},{"key":"1217_CR368","unstructured":"Corcept\u2019s dazucorilant fails to slow ALS progression in clinical trial, in Phase 2 DAZALS study enrolled 249 adults at multiple sites. 2024: ALS News Today."},{"issue":"1","key":"1217_CR369","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ajt.15533","volume":"20","author":"MA Podest\u00e0","year":"2020","unstructured":"Podest\u00e0 MA, et al. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro. Am J Transplant. 2020;20(1):88\u2013100.","journal-title":"Am J Transplant"},{"issue":"2","key":"1217_CR370","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","volume":"8","author":"G Herrero-Beaumont","year":"2012","unstructured":"Herrero-Beaumont G, Mart\u00ednez Calatrava MJ, Casta\u00f1eda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clin. 2012;8(2):78\u201383.","journal-title":"Reumatol Clin"},{"key":"1217_CR371","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Garc\u00eda R et al. Immune signaling kinases in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Int J Mol Sci. 2021;22(24).","DOI":"10.3390\/ijms222413280"},{"key":"1217_CR372","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3389\/fimmu.2019.02171","volume":"10","author":"FL Evans","year":"2019","unstructured":"Evans FL, et al. Protective and regenerative roles of T cells in central nervous system disorders. Front Immunol. 2019;10:2171.","journal-title":"Front Immunol"},{"key":"1217_CR373","unstructured":"Engensis gene therapy found safe in small phase 2a trial, in Helixmith's therapy has potential to promote nerve cell and muscle regeneration. 2022: ALS News Today."},{"issue":"9","key":"1217_CR374","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101169","volume":"4","author":"AR Ahmadi","year":"2023","unstructured":"Ahmadi AR, et al. A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects. Cell Rep Med. 2023;4(9): 101169.","journal-title":"Cell Rep Med"},{"key":"1217_CR375","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fnins.2020.00195","volume":"14","author":"E Geijo-Barrientos","year":"2020","unstructured":"Geijo-Barrientos E, et al. Intramuscular injection of bone marrow stem cells in amyotrophic lateral sclerosis patients: a randomized clinical trial. Front Neurosci. 2020;14:195.","journal-title":"Front Neurosci"},{"issue":"9","key":"1217_CR376","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","volume":"28","author":"RH Baloh","year":"2022","unstructured":"Baloh RH, et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial. Nat Med. 2022;28(9):1813\u201322.","journal-title":"Nat Med"},{"key":"1217_CR377","unstructured":"Verdiperstat fails to differentiate from placebo in critical HEALY ALS platform trial. 2022: Neurology Live."},{"issue":"2","key":"1217_CR378","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cpdd.1203","volume":"12","author":"L Gao","year":"2023","unstructured":"Gao L, et al. First-in-human studies of pharmacokinetics and safety of utreloxastat (PTC857), a novel 15-lipooxygenase inhibitor for the treatment of amyotrophic lateral sclerosis. Clin Pharmacol Drug Dev. 2023;12(2):141\u201351.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1217_CR379","unstructured":"BioJiva reports results of pilot phase 2 clinical trial of RT001 in patients with amyotrophic lateral sclerosis (ALS). 2022: GlobeNewswire."},{"key":"1217_CR380","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108380","volume":"182","author":"J Wen","year":"2021","unstructured":"Wen J, et al. Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1alpha\/Nrf2\/HO-1 pathway in ALS mice. Neuropharmacology. 2021;182: 108380.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1217_CR381","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.61055","volume":"8","author":"X Liu","year":"2025","unstructured":"Liu X, et al. Tetramethylpyrazine nitrone in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Netw Open. 2025;8(2): e2461055.","journal-title":"JAMA Netw Open"},{"key":"1217_CR382","unstructured":"Annual Report 2023: ARGX-119 development. 2023: Argenx."},{"issue":"9","key":"1217_CR383","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/13543784.2023.2263368","volume":"32","author":"S Vucic","year":"2023","unstructured":"Vucic S, Kiernan MC. Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS. Expert Opin Investig Drugs. 2023;32(9):783\u20135.","journal-title":"Expert Opin Investig Drugs"},{"key":"1217_CR384","unstructured":"New HEALEY-ALS trial results show CNM-AU8's effect on survival, neurofilament light. 2024: Neurology Live."},{"issue":"6","key":"1217_CR385","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/bph.15224","volume":"178","author":"M Herrando-Grabulosa","year":"2021","unstructured":"Herrando-Grabulosa M, et al. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178(6):1336\u201352.","journal-title":"Br J Pharmacol"},{"issue":"7_supplement_1","key":"1217_CR386","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1212\/WNL.0000000000206526","volume":"102","author":"J Shefner","year":"2024","unstructured":"Shefner J, et al. Pridopidine for the treatment of ALS\u2014Results from the phase 2 Healey ALS platform trial (S5.003). Neurology. 2024;102(7_supplement_1):6524.","journal-title":"Neurology"},{"key":"1217_CR387","unstructured":"NeuroSense Therapeutics plans to file for early commercialization of ALS treatment in Canada. 2024: PR Newswire."},{"issue":"21","key":"1217_CR388","doi-asserted-by":"publisher","first-page":"12275","DOI":"10.1021\/acs.jmedchem.0c00510","volume":"63","author":"T Felicetti","year":"2020","unstructured":"Felicetti T, Cecchetti V, Manfroni G. Modulating microRNA processing: enoxacin, the progenitor of a new class of drugs. J Med Chem. 2020;63(21):12275\u201389.","journal-title":"J Med Chem"},{"key":"1217_CR389","unstructured":"Magen I et al. A phase Ib\/IIa randomized trial of enoxacin in patients with ALS. medRxiv, 2024: p. 2024.07.31.24311258."},{"key":"1217_CR390","unstructured":"PLL Therapeutics obtains authorization to start phase I\/II trial in Australia for patients with amyotrophic lateral sclerosis (ALS). 2024: PLL Therapeutics."},{"key":"1217_CR391","unstructured":"Treatment for improving gut microbiome found safe in ALS, in Oral Therapy MaaT033 tested in phase 1B trial in patients in France. 2024: ALS News Today."},{"key":"1217_CR392","doi-asserted-by":"crossref","unstructured":"Lemarchant S et al. NX210c peptide promotes glutamatergic receptor-mediated synaptic transmission and signaling in the mouse central nervous system. Int J Mol Sci. 2022;23(16).","DOI":"10.3390\/ijms23168867"},{"key":"1217_CR393","unstructured":"Axoltis Pharma presents promising results from phase 1B clinical trial of innovative drug candidate for neurodegenerative diseases. 2023: ALA Associates."},{"key":"1217_CR394","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2015.10.006","volume":"85","author":"RT Bartus","year":"2016","unstructured":"Bartus RT, et al. beta2-Adrenoceptor agonists as novel, safe and potentially effective therapies for amyotrophic lateral sclerosis (ALS). Neurobiol Dis. 2016;85:11\u201324.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1217_CR395","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/CND.0000000000000438","volume":"24","author":"X Li","year":"2023","unstructured":"Li X, et al. Clenbuterol treatment is safe and associated with slowed disease progression in a small open-label trial in patients with amyotrophic lateral sclerosis. J Clin Neuromuscul Dis. 2023;24(4):214\u201321.","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01217-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:02:21Z","timestamp":1757516541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01217-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":395,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01217-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by the National Institutes of Health\/National Institute of Neurological Disorders and Stroke (R01NS120926 and R01NS127188 to S.A.G.), the Centers for Disease Control and Prevention\/Agency for Toxic Substances and Disease Registry (R01TS000344 and R01TS000327 to S.A.G.), and James and Margaret Hiller and Linda and Eric Novak (S.A.G.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S.A.G. is listed as inventor on a patent, issue number US10660895, held by University of Michigan titled \u201cMethods for Treating Amyotrophic Lateral Sclerosis\u201d that targets immune pathways for use in ALS therapeutics. Scientific consulting for Evidera. S.E.Q. and K.H.Q. have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.A.G. conceived the idea for the article. S.E.Q. and K.H.Q. performed the literature search, and all authors drafted, reviewed, and critically revised the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}